Business Case

Biomarker and combination assessment to define a data generation for a Prostate Cancer asset

Our client, a large biopharma company, wanted to extend the relevance of their prostate cancer therapy by investing in label-enabling activities. LSC was able to conduct research to identify and characterize biomarker and combination opportunities which were then prioritized for potential pursuit. The project resulted in the client initiating a number of clinical trial activities to expand their current label.